CD79b表达与突变在弥漫大B细胞淋巴瘤中的研究进展
Research Progress on CD79b Expression and Mutations in Diffuse Large B-Cell Lymphoma
摘要: 弥漫大B细胞淋巴瘤(Diffuse Large B-Cell Lymphoma, DLBCL)是最常见的侵袭性非霍奇金淋巴瘤，其分子的异质性显著，影响治疗反应和预后。B细胞受体(BCR)信号通路在DLBCL的发生发展中扮演核心角色，而CD79b作为BCR复合体的关键信号亚基，其表达水平和基因突变状态日益受到关注。CD79b与CD79a共同构成BCR的异源二聚体，负责抗原信号的传递，影响B细胞的活化与功能。本文综述了CD79b在DLBCL中的生物学功能、表达模式、基因突变特征及其靶向治疗的最新研究进展。重点探讨了CD79b异常与DLBCL分子分型、BCR信号通路持续活化以及新型靶向治疗策略之间的关系。
Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, with significant molecular heterogeneity that affects treatment response and prognosis. The B-Cell Receptor (BCR) signaling pathway plays a central role in the occurrence and development of DLBCL, and CD79b, as a key signaling subunit of the BCR complex, has increasingly attracted attention due to its expression level and gene mutation status. CD79b and CD79a together form the heterodimer of BCR, responsible for the transmission of antigen signals and influencing the activation and function of B cells. This article reviews the latest research progress on the biological function, expression pattern, gene mutation characteristics of CD79b in DLBCL, and its targeted therapy. It focuses on the relationship between CD79b abnormalities and DLBCL molecular typing, the continuous activation of the BCR signaling pathway, and new targeted therapy strategies.
文章引用：李祖燕, 姚锦. CD79b表达与突变在弥漫大B细胞淋巴瘤中的研究进展[J]. 临床医学进展, 2026, 16(4): 2273-2280. https://doi.org/10.12677/acm.2026.1641475

参考文献

[1] Isshiki, Y. and Melnick, A. (2021) Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). Current Cancer Drug Targets, 21, 274-282. [Google Scholar] [CrossRef] [PubMed]
[2] Vodicka, P., Klener, P. and Trneny, M. (2022) Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. OncoTargets and Therapy, 15, 1481-1501. [Google Scholar] [CrossRef] [PubMed]
[3] Veryaskina, Y.A., Titov, S.E., Kovynev, I.B., Fyodorova, S.S., Berezina, O.V., Zhurakovskij, I.P., et al. (2025) Micrornas in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential. Cancers, 17, Article 1300. [Google Scholar] [CrossRef] [PubMed]
[4] Weiss, J., Carty, S.A. and Karimi, Y.H. (2025) Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Cancers, 17, Article 2314. [Google Scholar] [CrossRef] [PubMed]
[5] Huse, K., Bai, B., Hilden, V.I., Bollum, L.K., Våtsveen, T.K., Munthe, L.A., et al. (2022) Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. The Journal of Immunology, 209, 2042-2053. [Google Scholar] [CrossRef] [PubMed]
[6] Grossmann, L., Jagla, W., Bettstetter, M., Bertz, S., Schwarz-Furlan, S., Richter, T., et al. (2025) Gene Expression Profiling Provides an Improved Characterization of Cd79b-Mutated Diffuse Large B-Cell Lymphomas. Journal of Personalized Medicine, 15, Article 548. [Google Scholar] [CrossRef] 
[7] Radke, J., Ishaque, N., Koll, R., Gu, Z., Schumann, E., Sieverling, L., et al. (2022) The Genomic and Transcriptional Landscape of Primary Central Nervous System Lymphoma. Nature Communications, 13, Article No. 2558. [Google Scholar] [CrossRef] [PubMed]
[8] Arai, A., Takase, H., Yoshimori, M., Yamamoto, K., Mochizuki, M. and Miura, O. (2020) Gene Expression Profiling of Primary Vitreoretinal Lymphoma. Cancer Science, 111, 1417-1421. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, P.M., Nejati, R., Lu, P., Thakkar, D., Mackrides, N., Dupoux, V., et al. (2023) Leukemic Presentation and Progressive Genomic Alterations of MCD/C5 Diffuse Large B-Cell Lymphoma (DLBCL). Molecular Case Studies, 9, a006283. [Google Scholar] [CrossRef] [PubMed]
[10] Flümann, R., Hansen, J., Meinel, J., Pfeiffer, P., Goldfarb Wittkopf, H., Lütz, A., et al. (2024) An Inducible CD79B Mutation Confers Ibrutinib Sensitivity in Mouse Models of Myd88-Driven Diffuse Large B-Cell Lymphoma. Blood Advances, 8, 1063-1074. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, Y., Ma, X., Wu, X., Hou, X., Jin, W., Fu, L., et al. (2024) Zanubrutinib Is Effective in Non-Germinal-Center B-Cell-Like Diffuse Large B-Cell Lymphoma with Mutated CD79B, High TCL1A Expression, or Over-Expressed MYC/BCL-2. Leukemia & Lymphoma, 65, 1079-1089. [Google Scholar] [CrossRef] [PubMed]
[12] Kaimi, Y., Shibata, M., Fukuhara, S., Takahashi, Y., Ochi, T., Makita, S., et al. (2025) Correlation with CD79B Expression and Clinicopathological Parameters Including Cell of Origin, CD79A and CD19 Expression, and CD79B Mutation in Diffuse Large B-Cell Lymphoma. Human Pathology, 160, Article 105852. [Google Scholar] [CrossRef] [PubMed]
[13] Meriranta, L., Sorri, S., Huse, K., Liu, X., Spasevska, I., Zafar, S., et al. (2024) Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma. Blood Cancer Discovery, 5, 331-352. [Google Scholar] [CrossRef] [PubMed]
[14] Pu, D., Liu, D., Li, C., Chen, C., Che, Y., Lv, J., et al. (2022) A Novel Ten-Gene Prognostic Signature for Cervical Cancer Based on CD79B-Related Immunomodulators. Frontiers in Genetics, 13, Article ID: 933798. [Google Scholar] [CrossRef] [PubMed]
[15] Xu, W., Berning, P. and Lenz, G. (2021) Targeting B-Cell Receptor and PI3K Signaling in Diffuse Large B-Cell Lymphoma. Blood, 138, 1110-1119. [Google Scholar] [CrossRef] [PubMed]
[16] Agostinelli, C., Morandi, L., Righi, S., Cirillo, L., Iommi, M., Tonon, C., et al. (2023) Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets. Modern Pathology, 36, Article 100323. [Google Scholar] [CrossRef] [PubMed]
[17] Walji, M. and Assouline, S. (2020) An Evaluation of Polatuzumab Vedotin for the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Expert Review of Hematology, 13, 933-942. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, R., Zhou, D., Wang, L., Zhu, L. and Ye, X. (2022) Myd88l265p and CD79B Double Mutations Type (MCD Type) of Diffuse Large B-Cell Lymphoma: Mechanism, Clinical Characteristics, and Targeted Therapy. Therapeutic Advances in Hematology, 13.
[19] Peng, F., Igawa, T., Kobayashi, H., Isoda, T., Ono, S. and Yamamoto, H. (2026) MYD88 and CD79B Mutation Analysis in Primary Pharyngeal Diffuse Large B‐Cell Lymphomas: Expanding the MCD‐Like Subtype from the Sinonasal Region to the Upper Airway. Pathology International, 76, e70071. [Google Scholar] [CrossRef] 
[20] Mandato, E., Yan, Q., Ouyang, J., Paczkowska, J., Qin, Y., Hao, Y., et al. (2023) MYD88L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas via an Interaction with Dock8. Blood, 142, 1219-1232. [Google Scholar] [CrossRef] [PubMed]
[21] Xu, P., Shen, R., Shi, Z., Cheng, S., Wang, L., Liu, Y., et al. (2022) The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-Analysis and Systematic Literature Review. Clinical Lymphoma Myeloma and Leukemia, 22, e1051-e1058.e1. [Google Scholar] [CrossRef] [PubMed]
[22] Bourbon, E. and Salles, G. (2020) Polatuzumab Vedotin: An Investigational Anti-CD79B Antibody Drug Conjugate for the Treatment of Diffuse Large B-Cell Lymphoma. Expert Opinion on Investigational Drugs, 29, 1079-1088. [Google Scholar] [CrossRef] [PubMed]
[23] Amaya, M.L., Jimeno, A., and Kamdar, M., (2020) Polatuzumab Vedotin to Treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma, in Combination with Bendamustine Plus Rituximab. Drugs of Today, 56, 287-294. [Google Scholar] [CrossRef] [PubMed]
[24] Camus, V. and Tilly, H. (2020) Polatuzumab Vedotin, an Anti-CD79B Antibody-Drug Conjugate for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Future Oncology, 17, 127-135. [Google Scholar] [CrossRef] [PubMed]
[25] Malecek, M., Watkins, M.P. and Bartlett, N.L. (2021) Polatuzumab Vedotin for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Expert Opinion on Biological Therapy, 21, 831-839. [Google Scholar] [CrossRef] [PubMed]
[26] Chu, F., Cao, J., Liu, J., Yang, H., Davis, T.J., Kuang, S., et al. (2023) Chimeric Antigen Receptor T Cells to Target CD79B in B-Cell Lymphomas. Journal for ImmunoTherapy of Cancer, 11, e007515. [Google Scholar] [CrossRef] [PubMed]
[27] Walker, J.S., Wenzl, K., Novak, J.P., Stokes, M.E., Hopper, M.A., Dropik, A.R., et al. (2025) Integrated Genomics with Refined Cell-of-Origin Subtyping Distinguishes Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B-Cell Lymphoma. Blood Cancer Journal, 15, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
[28] Abdur Raqib, M., Haseeb, A., Shafique, M.A., Fadlalla Ahmed, T.K. and Mustafa, M.S. (2023) Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma. Pediatric Health, Medicine and Therapeutics, 14, 323-331. [Google Scholar] [CrossRef] [PubMed]
[29] Corcoran, S.R., Phelan, J.D., Choi, J., Shevchenko, G., Fenner, R.E., Yu, X., et al. (2024) Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma. Cancer Discovery, 14, 1653-1674. [Google Scholar] [CrossRef] [PubMed]
[30] Renner, K., Neumayer, S., Talke, Y., Buchtler, S., Schmidbauer, K., Nimmerjahn, F., et al. (2022) B‐Cell Modulation with Anti‐CD79B Antibodies Ameliorates Experimental Autoimmune Encephalitis in Mice. European Journal of Immunology, 52, 656-668. [Google Scholar] [CrossRef] [PubMed]
[31] Kawasaki, N., Nishito, Y., Yoshimura, Y. and Yoshiura, S. (2022) The Molecular Rationale for the Combination of Polatuzumab Vedotin Plus Rituximab in Diffuse Large B‐Cell Lymphoma. British Journal of Haematology, 199, 245-255. [Google Scholar] [CrossRef] [PubMed]
[32] Leveille, E., Kothari, S., Cosgun, K.N., Mlynarczyk, C. and Müschen, M. (2024) Tuning Responses to Polatuzumab Vedotin in B-Cell Lymphoma. Cancer Discovery, 14, 1577-1580. [Google Scholar] [CrossRef] [PubMed]
[33] Wang, J., Li, C., He, K., Kuang, Z., Lu, J., Yao, Y., et al. (2023) Characterization of Anti-CD79B/CD3 Bispecific Antibody, a Potential Therapy for B Cell Malignancies. Cancer Immunology, Immunotherapy, 72, 493-507. [Google Scholar] [CrossRef] [PubMed]
[34] Leung, I., Templeton, M.L., Lo, Y., Rajan, A., Stull, S.M., Garrison, S.M., et al. (2023) Compromised Antigen Binding and Signaling Interfere with Bispecific CD19 and CD79A Chimeric Antigen Receptor Function. Blood Advances, 7, 2718-2730. [Google Scholar] [CrossRef] [PubMed]
[35] Atar, D., Mast, A., Scheuermann, S., Ruoff, L., Seitz, C.M. and Schlegel, P. (2022) Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas. Biomedicines, 10, Article 2420. [Google Scholar] [CrossRef] [PubMed]
[36] Dong, Y., Shi, Q., Wu, W., Zhao, B., Fu, D., Xu, P., et al. (2025) Characteristics and Predictive Model for Diffuse Large B-Cell Lymphoma with Early Chemoimmunotherapy Failure. Frontiers in Immunology, 16, Article ID: 1553850. [Google Scholar] [CrossRef] [PubMed]
[37] Almasri, M., Maher, N., Al Deeban, B., Diop, N.M., Moia, R. and Gaidano, G. (2025) Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside. International Journal of Molecular Sciences, 26, Article 4869. [Google Scholar] [CrossRef] [PubMed]

为你推荐